Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Current Status of Chemically Synthesized Inhibitors of Ebola Virus

Author(s): Anthony P. Cardile, Douglas L. Mayers and Sina Bavari

Volume 9, Issue 2, 2014

Page: [97 - 103] Pages: 7

DOI: 10.2174/1574891X10666150326114221

Price: $65

Abstract

The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.

Keywords: AVI-6002, AVI-7537, AVI-7539, BCX4430, brincidofovir, Ebola, favipiravir, TKM-100802.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy